Buy or sell HeartFlow stock pre IPO via an EquityZen fund
Cardiovascular application software
About HeartFlow Stock
HeartFlow is a medical technology company that provides non-invasive coronary artery disease detection services. The company's main product is HeartFlow FFRCT Analysis, which aims to help a physician evaluate whether a patient has significant coronary artery disease. HeartFlow FFRCT Analysis uses a CT scan that is ordered by a physician to generated a 3D model of the patient's coronary arteries. The analysis aims to calculate the amount of blockage in the arteries and the limited blood flow.
The company additionally offers HeartFlow Planner which allows physicians to model treatment strategies for coronary artery disease.
The company is currently operating with business as usual, albeit with smaller, isolated teams. HeartFlow is allowing for hospitals to divert resources toward COVID-19 by letting algorithms replace invasive procedures like angiograms.
Christopher K. Zarins and Charles Anthony Taylor founded Cardiovascular Simulation in 2007 that became HeartFlow in May 2009. The company is headquartered in Redwood City, California.
Chief Executive Officer & President
Executive Vice President and Chief Medical Officer
Chief Technology Officer and Founder
Chief Commercial Officer
Chief Ethics & Compliance Officer & General Counsel
Vice President and Chief People Officer
Founder, Senior Vice President of Medical Affairs
Christopher K. Zarins
Senior Vice President, Market Access and Reimbursement
Heather A. Brown
Senior Vice President, Clinical, Quality and Regulatory
Vice President, Chief Information Security Officer
BioWorld - Jan, 31 2020
businesswire - Sep, 12 2019
bioportfolio - May, 23 2019
computerworlduk - Feb, 21 2019
massdevice - Feb, 8 2019